High-Quality, Directly Sourced Primary Human Liver Cells

Our adult primary human hepatocyte inventory is richly annotated with clinical donor metadata, spanning both healthy-origin (normal BMI, no known fatty-liver disease) and diseased‐origin hepatocytes across the full spectrum of metabolic dysfunction (high BMI, MAFLD/NAFLD, steatosis, non-alcoholic steatohepatitis [MASH/NASH], and early fibrosis). The majority of our lots derive from healthy-origin donors, enabling baseline, “normal” hepatic responses. In parallel, we offer diseased-origin lots (steatosis, fibrosis, MASH) to support disease modelling, mechanistic investigation of metabolic liver disorders, and differential toxicity assays where the hepatic phenotype may influence drug disposition or safety. Benefits to researcher:

• Ability to directly compare compound responses in normal vs perturbed hepatocyte phenotype (e.g., healthy vs steatotic/MASH) to reveal subtle differences in metabolic clearance, transporter activity or toxicity risk in an at-risk population.
• Rich donor annotation (BMI, liver histopathology, fibrosis stage, genotyping) enables informed lot selection and biologically meaningful interpretation of results.
• Ideal for modelling metabolic liver disease progression, investigating DILI in the context of fatty liver disease, and supporting translational relevance in populations with metabolic dysfunction.

We offer cryopreserved primary human hepatocytes covering a full spectrum of early life stages—neonatal, pediatric, juvenile, adolescent—as well as adult. Age-dependent differences in hepatic function (e.g., enzymatic maturation, transporter expression, regenerative capacity) are increasingly recognized as key variables in preclinical and translational research. Younger-life-stage hepatocytes also provide additional utility in models supporting engraftment, regenerative medicine or developmental biology.

Benefits to researcher:

• Enables you to examine age-dependent differences in hepatic metabolism, transporter function, or toxicity (e.g., pediatric vs adult clearance, developmental susceptibility).
• Supports disease modelling or regenerative studies in younger-life-stage liver tissues where hepatocyte engraftment or maturation is relevant.
• Facilitates inclusion of age-appropriate hepatocyte substrates in safety, ADME or toxicology studies spanning the life-course.

Our induction-qualified hepatocyte lots have been rigorously characterized: every mid-term and long-term plateable lot is tested for baseline enzyme activity and for mRNA and specific activity induction of CYP1A2, CYP2B6 and CYP3A4 in response to prototypical inducers. Only lots that pass all induction parameters are offered in this category. Benefits to researcher:

• Optimized for induction assays — you can reliably select a lot that satisfies induction thresholds, reducing assay risk and variability.
• Accelerates your DDI (drug-drug interaction), metabolism and clearance screening workflows with confidence in lot performance.
• Simplifies lot selection by pre-qualifying based on induction criteria, saving you downstream qualification steps.

Our spheroid-qualified hepatocyte lots have been pre-tested and confirmed to self-assemble into 3D spheroid structures by day 7 and remain viable through day 21 in culture. Provided documentation includes images, ATP quantification at Days 7, 14 and 21, optimal seeding density and a detailed protocol to support spheroid formation. Benefits to researcher:

• Enables 3D hepatic modeling - more physiologically relevant cell–cell and cell–matrix interactions, enhanced longevity and improved functional stability versus 2D monolayers.
• Ideal for extended-duration studies (metabolism, toxicity, long-term clearance) in a more in vivo -like format.
• Increases translational relevance, particularly for applications such as DILI, chronic exposure, transporter studies and co-culture systems.

Our MPS-qualified hepatocyte lots have been validated for use in advanced microphysiological systems (MPS). They have been tested and pre-qualified for use in either our TruVivo^® advanced hepatic system or on CN Bio's PhysioMimix^® organ-on-a-chip range of MPS. Benefits to researcher:

• Ready-to-deploy hepatocytes for MPS workflows - minimizing upstream qualification time and risk.
• Enables higher‐complexity liver modelling (flow, multi‐cell type architecture, longevity) in various MPS formats.
• Supports advanced translational applications: chronic dosing, mechanistic toxicity, clearance modelling, tissue crosstalk and physiologically relevant microenvironment studies.